Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study.
Abdominal pain
Akkermansia
Diverticular disease
Eubiotic
Rifaximin
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
23 Mar 2023
23 Mar 2023
Historique:
received:
15
10
2022
accepted:
22
02
2023
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Rifaximin effectively treats symptomatic uncomplicated diverticular disease (SUDD) and has shown eubiotic potential (i.e., an increase in resident microbial elements with potential beneficial effects) in other diseases. This study investigated changes in the fecal microbiome of patients with SUDD after repeated monthly treatment with rifaximin and the association of these changes with the severity of abdominal pain. This was a single-center, prospective, observational, uncontrolled cohort study. Patients received rifaximin 400 mg twice a day for 7 days per month for 6 months. Abdominal pain (assessed on a 4-point scale from 0 [no pain] to 3 [severe pain]) and fecal microbiome (assessed using 16 S rRNA gene sequencing) were assessed at inclusion (baseline) and 3 and 6 months. The Spearman's rank test analyzed the relationship between changes in the gut microbiome and the severity of abdominal pain. A p-value ≤ 0.05 was considered statistically significant. Of the 23 patients enrolled, 12 patients completed the study and were included in the analysis. Baseline abdominal pain levels decreased significantly after 3 (p = 0.036) and 6 (p = 0.008) months of treatment with rifaximin. The abundance of Akkermansia in the fecal microbiome was significantly higher at 3 (p = 0.017) and 6 (p = 0.015) months versus baseline. The abundance of Ruminococcaceae (p = 0.034), Veillonellaceae (p = 0.028), and Dialister (p = 0.036) were significantly increased at 6 months versus baseline, whereas Anaerostipes (p = 0.049) was significantly decreased. The severity of abdominal pain was negatively correlated with the abundance of Akkermansia (r=-0.482; p = 0.003) and Ruminococcaceae (r=-0.371; p = 0.026) but not with Veillonellaceae, Dialister, or Anaerostipes. After 3 months of rifaximin, abdominal pain was significantly less in patients with Akkermansia in their fecal microbiome than in patients without Akkermansia (p = 0.022). The eubiotic effect of rifaximin was associated with decreased abdominal pain in patients with SUDD.
Sections du résumé
BACKGROUND
BACKGROUND
Rifaximin effectively treats symptomatic uncomplicated diverticular disease (SUDD) and has shown eubiotic potential (i.e., an increase in resident microbial elements with potential beneficial effects) in other diseases. This study investigated changes in the fecal microbiome of patients with SUDD after repeated monthly treatment with rifaximin and the association of these changes with the severity of abdominal pain.
METHODS
METHODS
This was a single-center, prospective, observational, uncontrolled cohort study. Patients received rifaximin 400 mg twice a day for 7 days per month for 6 months. Abdominal pain (assessed on a 4-point scale from 0 [no pain] to 3 [severe pain]) and fecal microbiome (assessed using 16 S rRNA gene sequencing) were assessed at inclusion (baseline) and 3 and 6 months. The Spearman's rank test analyzed the relationship between changes in the gut microbiome and the severity of abdominal pain. A p-value ≤ 0.05 was considered statistically significant.
RESULTS
RESULTS
Of the 23 patients enrolled, 12 patients completed the study and were included in the analysis. Baseline abdominal pain levels decreased significantly after 3 (p = 0.036) and 6 (p = 0.008) months of treatment with rifaximin. The abundance of Akkermansia in the fecal microbiome was significantly higher at 3 (p = 0.017) and 6 (p = 0.015) months versus baseline. The abundance of Ruminococcaceae (p = 0.034), Veillonellaceae (p = 0.028), and Dialister (p = 0.036) were significantly increased at 6 months versus baseline, whereas Anaerostipes (p = 0.049) was significantly decreased. The severity of abdominal pain was negatively correlated with the abundance of Akkermansia (r=-0.482; p = 0.003) and Ruminococcaceae (r=-0.371; p = 0.026) but not with Veillonellaceae, Dialister, or Anaerostipes. After 3 months of rifaximin, abdominal pain was significantly less in patients with Akkermansia in their fecal microbiome than in patients without Akkermansia (p = 0.022).
CONCLUSION
CONCLUSIONS
The eubiotic effect of rifaximin was associated with decreased abdominal pain in patients with SUDD.
Identifiants
pubmed: 36959568
doi: 10.1186/s12876-023-02690-x
pii: 10.1186/s12876-023-02690-x
pmc: PMC10037807
doi:
Substances chimiques
Rifaximin
L36O5T016N
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Informations de copyright
© 2023. The Author(s).
Références
J Gastrointestin Liver Dis. 2019 Sep 01;28(3):327-337
pubmed: 31517330
Benef Microbes. 2020 Oct 12;11(6):519-525
pubmed: 32885687
Prz Gastroenterol. 2019;14(1):69-78
pubmed: 30944680
J Biol Regul Homeost Agents. 2018 Nov-Dec;32(5):1421-1432
pubmed: 30574746
J Gastrointestin Liver Dis. 2020 Jan 08;28(suppl. 4):23-29
pubmed: 31930227
Microb Pathog. 2017 May;106:171-181
pubmed: 26875998
BMC Bioinformatics. 2016 Dec 1;17(1):491
pubmed: 27905885
Dig Dis. 2016;34(3):269-78
pubmed: 27027301
Gastroenterology. 2014 Feb;146(2):484-96.e4
pubmed: 24161699
Gut. 2017 Jul;66(7):1252-1261
pubmed: 27618836
Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101507
pubmed: 33642218
Dig Dis. 2018;36(1):56-65
pubmed: 28683448
Front Pharmacol. 2018 Nov 29;9:1340
pubmed: 30555323
PLoS One. 2013;8(4):e60042
pubmed: 23565181
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):423-430
pubmed: 33506932
J Investig Med. 2019 Apr;67(4):767-770
pubmed: 30593541
Clin Exp Gastroenterol. 2015 Dec 04;8:309-25
pubmed: 26673000
World J Gastrointest Pathophysiol. 2018 Feb 15;9(1):18-27
pubmed: 29487763
Mayo Clin Proc. 2016 Aug;91(8):1094-104
pubmed: 27156370
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Microbiology (Reading). 2017 May;163(5):646-648
pubmed: 28530168
World J Hepatol. 2021 May 27;13(5):557-570
pubmed: 34131470
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):8075-8083
pubmed: 31599433
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
EBioMedicine. 2021 Apr;66:103293
pubmed: 33813134
J Antimicrob Chemother. 2010 Dec;65(12):2556-65
pubmed: 20852272
J Gastrointestin Liver Dis. 2019 Jun 01;28:225-235
pubmed: 31204408
J Clin Gastroenterol. 2016 Oct;50 Suppl 1:S9-S12
pubmed: 27622378
Crit Rev Food Sci Nutr. 2020;60(13):2265-2276
pubmed: 31257904
PLoS One. 2015 Mar 06;10(3):e0119355
pubmed: 25748176
World J Gastroenterol. 2017 Jul 7;23(25):4491-4499
pubmed: 28740337
Nat Rev Dis Primers. 2020 Mar 26;6(1):20
pubmed: 32218442
Front Med (Lausanne). 2021 Jul 19;8:655474
pubmed: 34350192
Microb Biotechnol. 2019 Nov;12(6):1109-1125
pubmed: 31006995